Carcinoma of Unknown Primary: Molecular Tumor Board-based Therapy

Overview

Journal CA Cancer J Clin

Publisher Wiley

Specialty Oncology

Date 2022 Aug 25

PMID 36006378

Authors

Aditya V Shreenivas

Shumei Kato

Jingjing Hu

Catherine Skefos

Jason Sicklick

Razelle Kurzrock

Affiliations

Soon will be listed here.

References

Subbiah V, Kurzrock R . Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016; 2(6):719-20. DOI: 10.1001/jamaoncol.2016.0078. View

Ornitz D, Itoh N . The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015; 4(3):215-66. PMC: 4393358. DOI: 10.1002/wdev.176. View

Cady B . Basic principles in surgical oncology. Arch Surg. 1997; 132(4):338-46. DOI: 10.1001/archsurg.1997.01430280012001. View

Hemminki K, Bevier M, Hemminki A, Sundquist J . Survival in cancer of unknown primary site: population-based analysis by site and histology. Ann Oncol. 2011; 23(7):1854-63. DOI: 10.1093/annonc/mdr536. View

Demirci U, Coskun U, Karaca H, Dane F, Ozdemir N, Ulas A . Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev. 2014; 15(4):1581-4. DOI: 10.7314/apjcp.2014.15.4.1581. View

Javle M, Roychowdhury S, Kelley R, Sadeghi S, Macarulla T, Weiss K . Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021; 6(10):803-815. DOI: 10.1016/S2468-1253(21)00196-5. View

Kato S, Weipert C, Gumas S, Okamura R, Lee S, Sicklick J . Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. JCO Precis Oncol. 2021; 5. PMC: 8585281. DOI: 10.1200/PO.21.00011. View

Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A . Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002; 20(24):4679-83. DOI: 10.1200/JCO.2002.04.019. View

Kato S, Krishnamurthy N, Banks K, De P, Williams K, Williams C . Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017; 77(16):4238-4246. PMC: 5729906. DOI: 10.1158/0008-5472.CAN-17-0628. View

10.

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

11.

Ettinger D, Agulnik M, Cates J, Cristea M, Denlinger C, Eaton K . NCCN Clinical Practice Guidelines Occult primary. J Natl Compr Canc Netw. 2011; 9(12):1358-95. DOI: 10.6004/jnccn.2011.0117. View

12.

Kato S, Kim K, Lim H, Boichard A, Nikanjam M, Weihe E . Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020; 11(1):4965. PMC: 7532150. DOI: 10.1038/s41467-020-18613-3. View

13.

Pauli C, Bochtler T, Mileshkin L, Baciarello G, Losa F, Ross J . A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience. Oncologist. 2021; 26(5):e769-e779. PMC: 8100559. DOI: 10.1002/onco.13744. View

14.

Ross J, Wang K, Gay L, Otto G, White E, Iwanik K . Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. JAMA Oncol. 2015; 1(1):40-49. DOI: 10.1001/jamaoncol.2014.216. View

15.

Ong S, Guy G, Hadari Y, Laks S, Gotoh N, Schlessinger J . FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors. Mol Cell Biol. 2000; 20(3):979-89. PMC: 85215. DOI: 10.1128/MCB.20.3.979-989.2000. View

16.

Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B . Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019; 39 Suppl 1:7-18. DOI: 10.1111/liv.14093. View

17.

Fusco M, Saeed-Vafa D, Carballido E, Boyle T, Malafa M, Blue K . Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in Wild-Type Pancreatic Cancer. JCO Precis Oncol. 2021; 5. PMC: 8232071. DOI: 10.1200/PO.20.00265. View

18.

Krook M, Reeser J, Ernst G, Barker H, Wilberding M, Li G . Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance. Br J Cancer. 2020; 124(5):880-892. PMC: 7921129. DOI: 10.1038/s41416-020-01157-0. View

19.

Xie T, Zhang Z, Zhang X, Qi C, Shen L, Peng Z . Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:646355. PMC: 8440909. DOI: 10.3389/fonc.2021.646355. View

20.

Sicklick J, Kato S, Okamura R, Schwaederle M, Hahn M, Williams C . Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019; 25(5):744-750. PMC: 6553618. DOI: 10.1038/s41591-019-0407-5. View